Business Context and Reporting Period
Company: Actuate Therapeutics, Inc. (ACTU)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: Actuate is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor, for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) and pediatric malignancies. The company has no approved products and has not generated any revenue to date.
Key Subsequent Event: On August 14, 2024, the company completed its Initial Public Offering (IPO), raising approximately $22 million in net proceeds. The company also executed a 1-for-1.8 reverse stock split effective June 7, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6.57) million | $(5.52) million | $(14.87) million | $(10.79) million |
| Operating Expenses | $5.44 million | $5.58 million | $13.21 million | $10.88 million |
| Cash and Cash Equivalents (End of Period) | $0.35 million | $14.11 million | $0.35 million | $14.11 million |
| Working Capital Deficit | $(19.52) million | N/A | $(19.52) million | N/A |
| Accumulated Deficit | $(119.96) million | $(91.14) million | $(119.96) million | $(91.14) million |
Note: The company reported a significant fair value loss on related party convertible notes and warrant liabilities, contributing to the net loss.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses for the six months ended June 30, 2024, increased by $2.33 million (21%) compared to the same period in 2023. This was driven primarily by a $3.0 million increase in external clinical trial expenses due to patient enrollment in the Phase 2 mPDAC trial (Actuate-1801 Part 3B), partially offset by decreases in CMC costs and personnel fees.
- Other Income/Expense: The company recognized a $1.0 million loss on the change in estimated fair value of related party convertible notes and a $0.27 million loss on warrant liability changes for the six months ended June 30, 2024. These non-cash items were not present in the comparable 2023 period.
- Liquidity: Cash and cash equivalents decreased by $2.61 million during the first six months of 2024, compared to a decrease of $6.34 million in the same period in 2023. The company ended the period with only $0.35 million in cash, representing a critical liquidity position prior to the IPO.
- Debt: The company issued $5.5 million in related party convertible notes during the first half of 2024, which were subsequently converted into common stock upon the IPO closing.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that the company's financial condition raises substantial doubt about its ability to continue as a going concern as of June 30, 2024, due to the working capital deficit and lack of revenue. Management concluded that existing cash would not satisfy operational requirements for twelve months without additional funding.
- Capital Requirements: The company expects to incur significant operating losses for the foreseeable future. It requires substantial additional capital to fund clinical trials, regulatory filings, and commercialization efforts. The recent IPO proceeds are intended to address this, but management anticipates needing further financing.
- Clinical Development: The company is advancing a Phase 2 trial for mPDAC and a Phase 1/2 trial for pediatric malignancies. Success is entirely dependent on the development of elraglusib; failure to advance this single candidate would materially harm the business.
- Internal Controls: The company identified a material weakness in internal control over financial reporting as of December 31, 2023, related to the accrual of clinical trial expenses. Remediation procedures have been implemented.
- Supply Chain Risk: The company relies on a single manufacturer in China for the drug substance (DS) of elraglusib, creating potential geopolitical and supply chain risks.
Investor Verification Checklist
- Post-IPO Liquidity: Verify the actual cash balance and burn rate following the August 2024 IPO to confirm runway extension.
- Clinical Trial Progress: Monitor enrollment rates and interim data readouts for the Actuate-1801 (mPDAC) and pediatric trials.
- Debt Conversion: Confirm the final share count resulting from the conversion of the $5.5 million related party notes and preferred stock into common stock.
- Internal Control Remediation: Review future filings to ensure the material weakness regarding clinical expense accruals has been fully remediated.
- Manufacturing Dependencies: Assess the status of the Chinese drug substance manufacturer and any contingency plans for supply chain diversification.